Shelf life (days): 1460.0
Formulation: A crystalline solid
Formal Name: 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-(2S)-2-pyrrolidinecarboxamide
Purity: ≥98%
Formula Markup: C23H24FN9O
Formula Weight: 461.5
CAS Number: 1001350-96-4
Notes: BMS 754807 is a reversible, orally bioavailable dual inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine kinases (IC50s = 1.8 and 1.7 nM, respectively).{28722,28719} It has minimal effect against an array of other tyrosine and serine/threonine kinases.{28722} BMS 754807 inhibits cell proliferation or induces apoptosis in a variety of cancer cells in vitro.{28719} It inhibits the growth of tumor xenografts in mice and this effect is often enhanced by combination therapy with other chemotherapeutics.{28719,28718,28720} Predictive biomarkers, including elevated IGF-1R expression, for effectiveness of BMS 754807 have been delineated.{28721}
Deutsch
English
